David A Largaespada Selected Research

Transposases

2/2015	Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery.
11/2009	Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.
3/2009	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.
11/2005	Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse.
11/2005	Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma.
8/2004	Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Largaespada Research Topics

Disease

59	Neoplasms (Cancer) 08/2021 - 07/2003
11	Neurofibrosarcoma (MPNST) 03/2021 - 07/2013
10	Carcinogenesis 01/2020 - 03/2009
8	Neurofibroma 02/2021 - 07/2012
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 05/2006
7	Osteosarcoma (Osteogenic Sarcoma) 12/2020 - 06/2015
7	Leukemia 10/2016 - 04/2002
6	Neoplasm Metastasis (Metastasis) 10/2022 - 12/2016
6	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2021 - 02/2007
6	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 08/2004
5	Glioma (Gliomas) 01/2021 - 11/2005
5	Plexiform Neurofibroma 01/2021 - 03/2014
4	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2007
4	Brain Neoplasms (Brain Tumor) 01/2019 - 01/2009
4	Medulloblastoma 01/2019 - 02/2012
4	Myeloid Leukemia (Leukemia, Myelocytic) 10/2016 - 04/2002
3	Inflammation (Inflammations) 08/2021 - 01/2019
3	Neurofibromatoses (Neurofibromatosis) 01/2021 - 07/2013
3	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 03/2009
2	Breast Neoplasms (Breast Cancer) 10/2022 - 09/2015
2	Adenocarcinoma 01/2021 - 04/2012
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 03/2009
2	Liver Neoplasms (Liver Cancer) 01/2019 - 05/2012
2	Carcinoma (Carcinomatosis) 11/2017 - 11/2005
2	Nerve Sheath Neoplasms (Nerve Sheath Neoplasm) 07/2012 - 01/2012
2	Lymphoma (Lymphomas) 11/2009 - 04/2002
2	Prostatic Neoplasms (Prostate Cancer) 05/2009 - 01/2007
1	Hypertrophy 04/2021
1	Animal Disease Models 02/2021
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2021
1	Obesity 02/2020
1	Central Nervous System Neoplasms 01/2020
1	Hepatomegaly 11/2019
1	Non-alcoholic Fatty Liver Disease 03/2019
1	Chronic Hepatitis B 01/2019
1	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/2019

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 04/2021 - 04/2005
11	RNA (Ribonucleic Acid)IBA 10/2022 - 05/2010
7	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 04/2005
6	Small Interfering RNA (siRNA)IBA 01/2021 - 03/2011
6	Pharmaceutical PreparationsIBA 01/2020 - 01/2009
6	TransposasesIBA 02/2015 - 08/2004
5	CateninsIBA 03/2021 - 03/2011
4	Biological ProductsIBA 02/2021 - 08/2015
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 11/2014
4	ErbB Receptors (EGF Receptor)IBA 07/2014 - 01/2012
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 05/2010
3	Phosphotransferases (Kinase)IBA 01/2021 - 09/2015
3	LigandsIBA 01/2021 - 06/2013
3	Neurofibromin 1 (Neurofibromin)IBA 01/2018 - 02/2007
3	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 12/2016 - 07/2003
3	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2016 - 05/2006
3	Transcription Factors (Transcription Factor)IBA 07/2016 - 05/2012
3	AntigensIBA 01/2016 - 10/2013
3	MutagensIBA 08/2015 - 01/2007
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2021 - 11/2017
2	Calcibiotic Root Canal SealerIBA 01/2021 - 03/2009
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 11/2014
2	AZD 6244IBA 01/2021 - 01/2021
2	Mitogen-Activated Protein KinasesIBA 01/2020 - 11/2005
2	Complementary DNA (cDNA)IBA 01/2020 - 04/2005
2	VaccinesIBA 01/2020 - 10/2013
2	Guanosine Triphosphate (GTP)IBA 01/2019 - 08/2007
2	CytokinesIBA 10/2016 - 09/2014
2	Transcription Activator-Like Effector NucleasesIBA 01/2016 - 08/2014
2	DNA Transposable Elements (Element, IS)IBA 08/2015 - 01/2007
2	parthenolideIBA 08/2015 - 06/2015
2	Retroelements (Retrotransposon)IBA 09/2013 - 04/2013
2	ElementsIBA 04/2013 - 08/2007
2	TensinsIBA 07/2012 - 01/2012
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 07/2012 - 01/2012
2	Trans-Activators (Trans-Acting Factor)IBA 01/2009 - 08/2007
2	Tetracycline (Achromycin)FDA LinkGeneric 01/2009 - 08/2007
2	LuciferasesIBA 11/2005 - 08/2004
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	G-Protein-Coupled Receptor KinasesIBA 10/2022
1	muskIBA 10/2022
1	Interferon Type IIBA 01/2021
1	CytosineIBA 12/2020
1	Antiviral Agents (Antivirals)IBA 12/2020
1	NucleosidesIBA 12/2020
1	triciribineIBA 12/2020
1	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2020
1	pexidartinibIBA 01/2020
1	NestinIBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Semaphorins (Semaphorin)IBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Proto-Oncogene Proteins c-metIBA 01/2020
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2019
1	Interleukin-1beta (Interleukin 1 beta)IBA 03/2019
1	Transforming Growth Factor beta (TGF-beta)IBA 03/2019
1	tanshinone II A sodium sulfonateIBA 03/2019
1	ProstaglandinsIBA 01/2019

Therapy/Procedure

29	Therapeutics 02/2021 - 08/2004
4	Drug Therapy (Chemotherapy) 01/2020 - 05/2006
3	Immunotherapy 01/2021 - 09/2013
3	Transplantation 11/2020 - 03/2016
1	Precision Medicine 01/2021